Summary of Study ST002729
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001693. The data can be accessed directly via it's Project DOI: 10.21228/M8VT66 This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.
| Study ID | ST002729 |
| Study Title | Improved Endurance Capacity of Diabetic Mice during SGLT2 Inhibition: Potential Role of AICARP, an Endogenous AMPK Activator. |
| Study Summary | Diabetes is associated with an increased risk of deleterious changes in muscle mass and function or sarcopenia, leading to physical inactivity and worsening glycemic control. Given the negative energy balance during sodium-glucose cotransporter 2 (SGLT2) inhibition, whether SGLT2 inhibitors affect skeletal muscle mass and function is a matter of concern. However, how SGLT2 inhibition affects the skeletal muscle function in patients with diabetes remains insufficiently explored. We aimed to explore the effects of canagliflozin (CANA), an SGLT2 inhibitor, on skeletal muscles in genetically diabetic db/db mice. |
| Institute | Medical Institute of Bioregulation, Kyushu University |
| Last Name | Takahashi |
| First Name | Masatomo |
| Address | Maidashi 3-1-1, Higashi-ku, Fukuoka, Fukuoka, 8128582, Japan |
| m-takahashi@bioreg.kyushu-u.ac.jp | |
| Phone | 0926426171 |
| Submit Date | 2023-05-25 |
| Raw Data Available | Yes |
| Raw Data File Type(s) | mzML, mzXML, lcd |
| Analysis Type Detail | LC-MS |
| Release Date | 2023-11-09 |
| Release Version | 1 |
Select appropriate tab below to view additional metadata details:
Treatment:
| Treatment ID: | TR002844 |
| Treatment Summary: | All mice were free access to normal chow diet and water. CANA was mixed at 0.03% (w/w) with CRF-1 and administered to 8-week-old db/+ and db/db mice for 4 weeks. |
